Filing Details

Accession Number:
0001415889-24-000771
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-05 16:06:08
Reporting Period:
2024-01-04
Accepted Time:
2024-01-05 16:06:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479419 Kala Bio Inc. KALA Pharmaceutical Preparations (2834) 270604595
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1893729 Darius Kharabi C/O Kala Bio, Inc.
1167 Massachusetts Avenue
Arlington MA 02476
Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-04 4,600 $0.00 66,502 No 4 A Direct
Common Stock Disposition 2024-01-04 1,385 $6.73 65,117 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2024-01-04 20,500 $0.00 20,500 $7.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,500 2034-01-03 No 4 A Direct
Footnotes
  1. Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027.
  2. Includes 53,620 unvested RSUs.
  3. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  5. Includes 50,446 unvested RSUs.
  6. This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer.